Assess the Role of the New COVID-19 MAb, Bebtelovimab

March 2022

Bebtelovimab will expand monoclonal antibody (MAb) options for high-risk patients with mild to moderate COVID-19.

The Omicron variant limits OUTpatient MAb treatment options to sotrovimab. Now bebtelovimab is another choice for COVID-19 patients who are at high risk of severe illness (diabetes, etc).

Similar to sotrovimab, bebtelovimab is for adults...or kids age 12 and up who weigh 40 kg or more...and is provided at no cost.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Immunizations Clarify New Guidelines for Prevnar 20 and Vaxneuvance
Corticosteroids Be Equipped With Rules of Thumb to Taper Steroids
Insulin Implement Safeguards for U-500 Insulin
Mental Health Be Ready to Ask Questions About Suicide
Pediatrics Shorten Antibiotic Durations for Kids With Community-Acquired Pneumonia
Neurology & Pain Compare Meds for Diabetic Neuropathy
Oral Health Reinforce Oral Care With Buccal or Sublingual Buprenorphine
Insomnia Be Prepared With Answers About Melatonin for Sleep
Eczema Watch for Adbry, Cibinqo, and Rinvoq for Eczema
Infectious Diseases Optimize Antibiotic Stewardship for Gram-Negative Bacteremia
COVID-19 Assess the Role of the New COVID-19 MAb, Bebtelovimab
Critical Care Prevent Withdrawal Due to ICU Analgesics and Sedatives

Assess the Role of the New COVID-19 MAb, Bebtelovimab

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents